CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response (MPR) rates compared with chemotherapy alone in resectable EGFR-mutant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results